Gut microbiota and outcomes in DLBCL, NFIA-ETO2 fusion cooperates with TP53 in leukemogenesis, and the impact of nirmatrelvir + ritonavir on CLL patient outcomes during the Omicron surge
Blood Podcast
00:00
Introduction
Imbalances in gut microbiota may impact the efficacy and safety of immuno-chemo therapy in patients with diffuse large B cell lymphoma. NF1A ETO2 fusion found exclusively in pediatric patients with pure erythroid leukemia, impairs the normal process of differentiation. Nirmatrelvia plus ritonovia was linked to a lower rate of COVID-19-related hospitalization and mortality for CLL infected with SARS-CoV-2 during the Omochron surge.
Transcript
Play full episode
